Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Prima BioMed to Present at ISBioTech Annual Meeting


Prima BioMed to Present at ISBioTech Annual Meeting

SYDNEY, AUSTRALIA -- (Marketwire) -- 03/10/13 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," "the Company") announces that its Vice President of Manufacturing, Marta Schilling, will present at the 3rd annual meeting of the International Society for BioProcess Technology (ISBioTech) to be held in Rosslyn, Virginia.

"The Challenges of Harmonizing cGMP Manufacturing Across Multiple CMOs on Different Continents" will be delivered at 10:30am (local time) on March 13, 2013. Ms. Schilling will present on the challenges of harmonizing manufacturing for personalized immunocellular products in multiple facilities in different regions. She will also review Prima's accomplishments in the successful implementation of harmonized manufacturing among the Company's three CVac manufacturing facilities in Australia, the USA, and Germany.

Ms. Schilling: "I am pleased to have been given the opportunity to present at the ISBioTech conference. There is significant industry interest in Prima's operational, logistical, and technical accomplishments to support the consistent global manufacture of a product like CVac."

About Prima BioMed Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and to maximize value to shareholders. Prima's lead product is CVac(TM), an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.

For further information please contact:

USA Investor/Media: Ms. Jessica Brown Prima BioMed Ltd. +1 (919) 710-9061 jessica.brown@primabiomed.com.au

Australia Investor/Media: Mr. James Moses Mandate Corporate +61 (0) 420 991 574 james@mandatecorporate.com.au

Europe Investor/Media: Mr. Axel Muhlhaus edicto GmbH +49 (0) 69 905505-52 amuehlhaus@edicto.de

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement